This inventor holds 5 USPTO granted patents and 2 published patent applications. Top assignee: Novartis Ag. Active years: 2010-2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Vienna, AT (2010)
- Allschwil, CH (2014 - 2015)
Company Filing History:
Years Active: 2010-2015
Title: Innovations of Jose M Carballido Herrera
Introduction
Jose M Carballido Herrera is a prominent inventor based in Allschwil, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. With a total of 5 patents, his work focuses on addressing autoimmune and inflammatory disorders.
Latest Patents
One of his latest patents is titled "Anti-IL12Rβ1 antibodies and their use in treating autoimmune and inflammatory disorders." This invention relates to antibodies that specifically bind to IL12Rβ1, which is the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention details specific antibodies that act as IL12 and IL23 receptor antagonists. These antibodies are capable of inhibiting IL12/IL18 induced IFNγ production of blood cells. The compositions and methods of use for these antibodies aim to treat pathological disorders that can be managed by inhibiting IFNγ production, IL12, and IL23 signaling. Such disorders include rheumatoid arthritis, psoriasis, inflammatory bowel diseases, and other autoimmune and inflammatory conditions.
Career Highlights
Jose M Carballido Herrera is associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on innovative solutions for complex health issues. His contributions have been instrumental in advancing therapeutic options for patients suffering from various autoimmune diseases.
Collaborations
Throughout his career, Jose has collaborated with notable colleagues, including Christoph Heusser and Christoph Schwaerzler. These collaborations have further enhanced the research and development of effective treatments in the field of immunology.
Conclusion
Jose M Carballido Herrera's innovative work in the development of therapeutic antibodies has made a significant impact on the treatment of autoimmune and inflammatory disorders. His contributions continue to shape the future of biotechnology and patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile